Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.

Inclusion Criteria:

• Subject is a good candidate to receive infliximab as per the Product Monograph
• Subject is prescribed infliximab by an appropriate physician
• Subject receives infusion in a community infusion centre.
• Subject has signed the approved consent form.

Exclusion Criteria:

• Not specified in the protocol

The data captured and reported in this registry will reflect a "real world" approach to the treatment of Rheumatoid Arthritis and Crohn's Disease with infliximab.